147 related articles for article (PubMed ID: 10499482)
41. Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis.
Vasen HF; Bülow S; Myrhøj T; Mathus-Vliegen L; Griffioen G; Buskens E; Taal BG; Nagengast F; Slors JF; de Ruiter P
Gut; 1997 Jun; 40(6):716-9. PubMed ID: 9245923
[TBL] [Abstract][Full Text] [Related]
42. Phenotype and management of patients with familial adenomatous polyposis in Hong Kong: perspective of the Hereditary Gastrointestinal Cancer Registry.
Ho JW; Chu KM; Tse CW; Yuen ST
Hong Kong Med J; 2002 Oct; 8(5):342-7. PubMed ID: 12376711
[TBL] [Abstract][Full Text] [Related]
43. Duodenal surveillance improves the prognosis after duodenal cancer in familial adenomatous polyposis.
Bülow S; Christensen IJ; Højen H; Björk J; Elmberg M; Järvinen H; Lepistö A; Nieuwenhuis M; Vasen H
Colorectal Dis; 2012 Aug; 14(8):947-52. PubMed ID: 21973191
[TBL] [Abstract][Full Text] [Related]
44. Progression and Management of Duodenal Neoplasia in Familial Adenomatous Polyposis: A Cohort Study.
Serrano PE; Grant RC; Berk TC; Kim D; Al-Ali H; Cohen Z; Pollett A; Riddell R; Silverberg MS; Kortan P; May GR; Gallinger S
Ann Surg; 2015 Jun; 261(6):1138-44. PubMed ID: 24950262
[TBL] [Abstract][Full Text] [Related]
45. Desmoid tumor patients carry an elevated risk of familial adenomatous polyposis.
Koskenvuo L; Peltomäki P; Renkonen-Sinisalo L; Gylling A; Nieminen TT; Ristimäki A; Lepistö A
J Surg Oncol; 2016 Feb; 113(2):209-12. PubMed ID: 26663236
[TBL] [Abstract][Full Text] [Related]
46. The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment.
Iwama T; Mishima Y; Utsunomiya J
Ann Surg; 1993 Feb; 217(2):101-8. PubMed ID: 8382467
[TBL] [Abstract][Full Text] [Related]
47. Mesenteric desmoid tumors in Singapore familial adenomatous polyposis patients: clinical course and genetic profile in a predominantly Chinese population.
Koh PK; Loi C; Cao X; Cheah PY; Ho KS; Ooi BS; Tang CL; Eu KW
Dis Colon Rectum; 2007 Jan; 50(1):75-82. PubMed ID: 17082890
[TBL] [Abstract][Full Text] [Related]
48. CT appearances of desmoid tumours in familial adenomatous polyposis: further observations.
Brooks AP; Reznek RH; Nugent K; Farmer KC; Thomson JP; Phillips RK
Clin Radiol; 1994 Sep; 49(9):601-7. PubMed ID: 7955885
[TBL] [Abstract][Full Text] [Related]
49. [Desmoid tumors in patients with familial adenomatous polyposis].
Pikaar A; Nortier JW; Griffioen G; Vasen HF
Ned Tijdschr Geneeskd; 2002 Jul; 146(29):1355-9. PubMed ID: 12162172
[TBL] [Abstract][Full Text] [Related]
50. Familial adenomatous polyposis in pediatrics: natural history, emerging surveillance and management protocols, chemopreventive strategies, and areas of ongoing debate.
Septer S; Lawson CE; Anant S; Attard T
Fam Cancer; 2016 Jul; 15(3):477-85. PubMed ID: 27056662
[TBL] [Abstract][Full Text] [Related]
51. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study.
Nieuwenhuis MH; Lefevre JH; Bülow S; Järvinen H; Bertario L; Kernéis S; Parc Y; Vasen HF
Dis Colon Rectum; 2011 Oct; 54(10):1229-34. PubMed ID: 21904137
[TBL] [Abstract][Full Text] [Related]
52. Tailored surgical treatment of duodenal polyposis in familial adenomatous polyposis syndrome.
Augustin T; Moslim MA; Tang A; Walsh RM
Surgery; 2018 Mar; 163(3):594-599. PubMed ID: 29331402
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic approaches for patients with coexisting familial adenomatous polyposis and colorectal cancer.
Inoue Y; Ishida H; Ueno H; Kobayashi H; Yamaguchi T; Konishi T; Tomita N; Matsubara N; Ishida F; Hinoi T; Kanemitsu Y; Watanabe T; Sugihara K
Jpn J Clin Oncol; 2016 Sep; 46(9):819-24. PubMed ID: 27418167
[TBL] [Abstract][Full Text] [Related]
54. Desmoid tumours in familial adenomatous polyposis.
Gurbuz AK; Giardiello FM; Petersen GM; Krush AJ; Offerhaus GJ; Booker SV; Kerr MC; Hamilton SR
Gut; 1994 Mar; 35(3):377-81. PubMed ID: 8150351
[TBL] [Abstract][Full Text] [Related]
55. Outcome of familial adenomatous polyposis: a retrospective study.
Sahakitrungruang C; Kanjanasilp P; Pattana-Arun J; Tantiphlachiva K; Rojanasakul A
J Med Assoc Thai; 2006 Sep; 89 Suppl 3():S155-60. PubMed ID: 17718282
[TBL] [Abstract][Full Text] [Related]
56. [Impact of a registry on survival in familial adenomatous polyposis].
Reyes Moreno J; Ginard Vicens D; Vanrell M; Mariñó Z; Garau I; Llompart A; Obrador Adrover A
Med Clin (Barc); 2007 Jun; 129(2):51-2. PubMed ID: 17588361
[TBL] [Abstract][Full Text] [Related]
57. Prophylaxis against colorectal cancer.
Bülow S; Kronborg O
Scand J Gastroenterol Suppl; 1996; 216():160-8. PubMed ID: 8726288
[TBL] [Abstract][Full Text] [Related]
58. Ureteric obstruction in familial adenomatous polyposis-associated desmoid disease.
Joyce M; Mignanelli E; Church J
Dis Colon Rectum; 2010 Mar; 53(3):327-32. PubMed ID: 20173481
[TBL] [Abstract][Full Text] [Related]
59. The impact of chromoendoscopy for surveillance of the duodenum in patients with MUTYH-associated polyposis and familial adenomatous polyposis.
Hurley JJ; Thomas LE; Walton SJ; Thomas-Gibson S; Haycock A; Suzuki N; Mort M; Williams G; Morgan M; Clark SK; Sampson JR; Dolwani S
Gastrointest Endosc; 2018 Oct; 88(4):665-673. PubMed ID: 29702101
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
